• Something wrong with this record ?

Severity of Ischemic Stroke After Left Atrial Appendage Closure vs Nonwarfarin Oral Anticoagulants

MK. Turagam, I. Kawamura, P. Neuzil, D. Nair, S. Doshi, M. Valderrabano, P. Hala, D. Della Rocca, D. Gibson, M. Funasako, G. Ha, B. Lee, D. Musikantow, D. Yoo, T. Flautt, S. Dukkipati, A. Natale, ME. Gurol, J. Halperin, M. Mansour, VY. Reddy

. 2024 ; 10 (2) : 270-283. [pub] 20231122

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc24007391

BACKGROUND: Strokes after left atrial appendage closure (LAAC) prophylaxis are generally less severe than those after warfarin prophylaxis-thought to be secondary to more hemorrhagic strokes with warfarin. Hemorrhagic strokes are similarly infrequent with direct oral anticoagulant (DOAC) prophylaxis, so the primary subtype after either LAAC or DOAC prophylaxis is ischemic stroke (IS). OBJECTIVES: The purpose of this study was to compare the severity of IS using the modified Rankin Scale in atrial fibrillation patients receiving prophylaxis with DOACs vs LAAC. METHODS: A retrospective analysis was performed of consecutive patients undergoing LAAC at 8 centers who developed an IS (ISLAAC) compared with contemporaneous consecutive patients who developed IS during treatment with DOACs (ISDOAC). The primary outcome was disabling/fatal stroke (modified Rankin Scale 3-5) at discharge and 3 months later. RESULTS: Compared with ISDOAC patients (n = 322), ISLAAC patients (n = 125) were older (age 77.2 ± 13.4 years vs 73.1 ± 11.9 years; P = 0.002), with higher HAS-BLED scores (3.0 vs 2.0; P = 0.004) and more frequent prior bleeding events (54.4% vs 23.6%; P < 0.001), but similar CHA2DS2-VASc scores (5.0 vs 5.0; P = 0.28). Strokes were less frequently disabling/fatal with ISLAAC than ISDOAC at both hospital discharge (38.3% vs 70.3%; P < 0.001) and 3 months later (33.3% vs 56.2%; P < 0.001). Differences in stroke severity persisted after propensity score matching. By multivariate regression analysis, ISLAAC was independently associated with fewer disabling/fatal strokes at discharge (OR: 0.22; 95% CI: 0.13-0.39; P < 0.001) and 3 months (OR: 0.25; 95% CI: 0.12-0.50; P < 0.001), and fewer deaths at 3 months (OR: 0.28; 95% CI: 0.12-0.64; P < 0.001). CONCLUSIONS: Ischemic strokes in patients with atrial fibrillation are less often disabling or fatal with LAAC than DOAC prophylaxis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007391
003      
CZ-PrNML
005      
20240423155923.0
007      
ta
008      
240412s2024 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jacep.2023.10.012 $2 doi
035    __
$a (PubMed)37999669
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Turagam, Mohit K $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
245    10
$a Severity of Ischemic Stroke After Left Atrial Appendage Closure vs Nonwarfarin Oral Anticoagulants / $c MK. Turagam, I. Kawamura, P. Neuzil, D. Nair, S. Doshi, M. Valderrabano, P. Hala, D. Della Rocca, D. Gibson, M. Funasako, G. Ha, B. Lee, D. Musikantow, D. Yoo, T. Flautt, S. Dukkipati, A. Natale, ME. Gurol, J. Halperin, M. Mansour, VY. Reddy
520    9_
$a BACKGROUND: Strokes after left atrial appendage closure (LAAC) prophylaxis are generally less severe than those after warfarin prophylaxis-thought to be secondary to more hemorrhagic strokes with warfarin. Hemorrhagic strokes are similarly infrequent with direct oral anticoagulant (DOAC) prophylaxis, so the primary subtype after either LAAC or DOAC prophylaxis is ischemic stroke (IS). OBJECTIVES: The purpose of this study was to compare the severity of IS using the modified Rankin Scale in atrial fibrillation patients receiving prophylaxis with DOACs vs LAAC. METHODS: A retrospective analysis was performed of consecutive patients undergoing LAAC at 8 centers who developed an IS (ISLAAC) compared with contemporaneous consecutive patients who developed IS during treatment with DOACs (ISDOAC). The primary outcome was disabling/fatal stroke (modified Rankin Scale 3-5) at discharge and 3 months later. RESULTS: Compared with ISDOAC patients (n = 322), ISLAAC patients (n = 125) were older (age 77.2 ± 13.4 years vs 73.1 ± 11.9 years; P = 0.002), with higher HAS-BLED scores (3.0 vs 2.0; P = 0.004) and more frequent prior bleeding events (54.4% vs 23.6%; P < 0.001), but similar CHA2DS2-VASc scores (5.0 vs 5.0; P = 0.28). Strokes were less frequently disabling/fatal with ISLAAC than ISDOAC at both hospital discharge (38.3% vs 70.3%; P < 0.001) and 3 months later (33.3% vs 56.2%; P < 0.001). Differences in stroke severity persisted after propensity score matching. By multivariate regression analysis, ISLAAC was independently associated with fewer disabling/fatal strokes at discharge (OR: 0.22; 95% CI: 0.13-0.39; P < 0.001) and 3 months (OR: 0.25; 95% CI: 0.12-0.50; P < 0.001), and fewer deaths at 3 months (OR: 0.28; 95% CI: 0.12-0.64; P < 0.001). CONCLUSIONS: Ischemic strokes in patients with atrial fibrillation are less often disabling or fatal with LAAC than DOAC prophylaxis.
650    _2
$a lidé $7 D006801
650    _2
$a lidé středního věku $7 D008875
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a warfarin $x škodlivé účinky $7 D014859
650    12
$a fibrilace síní $x komplikace $x farmakoterapie $x chirurgie $7 D001281
650    12
$a ischemická cévní mozková příhoda $x chemicky indukované $x komplikace $x farmakoterapie $7 D000083242
650    12
$a hemoragická cévní mozková příhoda $x chemicky indukované $x komplikace $x farmakoterapie $7 D000083302
650    _2
$a retrospektivní studie $7 D012189
650    _2
$a uzávěr ouška levé síně $7 D000097546
650    _2
$a výsledek terapie $7 D016896
650    _2
$a antikoagulancia $x škodlivé účinky $7 D000925
650    12
$a cévní mozková příhoda $x epidemiologie $x etiologie $x prevence a kontrola $7 D020521
650    _2
$a krvácení $x chemicky indukované $7 D006470
655    _2
$a časopisecké články $7 D016428
700    1_
$a Kawamura, Iwanari $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
700    1_
$a Neuzil, Petr $u Homolka Hospital, Prague, Czech Republic
700    1_
$a Nair, Devi $u St. Bernard's Heart and Vascular Center, Jonesboro, Arkansas, USA
700    1_
$a Doshi, Shephal $u Pacific Heart Institute, Santa Monica, California, USA
700    1_
$a Valderrabano, Miguel $u Houston Methodist, Houston, Texas, USA
700    1_
$a Hala, Pavel $u Homolka Hospital, Prague, Czech Republic
700    1_
$a Della Rocca, Domenico $u Texas Cardiac Arrhythmia Institute, Houston, Texas, USA
700    1_
$a Gibson, Douglas $u Scripps Health, San Diego, California, USA
700    1_
$a Funasako, Moritoshi $u Homolka Hospital, Prague, Czech Republic
700    1_
$a Ha, Grace $u Massachusetts General Hospital, Boston, Massachusetts, USA
700    1_
$a Lee, Bridget $u St. Bernard's Heart and Vascular Center, Jonesboro, Arkansas, USA
700    1_
$a Musikantow, Daniel $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
700    1_
$a Yoo, David $u Scripps Health, San Diego, California, USA
700    1_
$a Flautt, Thomas $u Houston Methodist, Houston, Texas, USA
700    1_
$a Dukkipati, Srinivas $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
700    1_
$a Natale, Andrea $u Texas Cardiac Arrhythmia Institute, Houston, Texas, USA
700    1_
$a Gurol, Mahmut E $u Massachusetts General Hospital, Boston, Massachusetts, USA
700    1_
$a Halperin, Jonathan $u Icahn School of Medicine at Mount Sinai, New York, New York, USA
700    1_
$a Mansour, Moussa $u Massachusetts General Hospital, Boston, Massachusetts, USA
700    1_
$a Reddy, Vivek Y $u Icahn School of Medicine at Mount Sinai, New York, New York, USA. Electronic address: vivek.reddy@mountsinai.org
773    0_
$w MED00193518 $t JACC. Clinical electrophysiology $x 2405-5018 $g Roč. 10, č. 2 (2024), s. 270-283
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37999669 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423155919 $b ABA008
999    __
$a ok $b bmc $g 2081393 $s 1217158
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 10 $c 2 $d 270-283 $e 20231122 $i 2405-5018 $m JACC. Clinical electrophysiology $n JACC Clin Electrophysiol $x MED00193518
LZP    __
$a Pubmed-20240412

Find record

Citation metrics

Archiving options